Johnson & Johnson $JNJ Shares Sold by Fortis Capital Advisors LLC

Key Points

• Fortis Capital Advisors LLC significantly reduced its stake in Johnson & Johnson by 86.2% during the second quarter, leaving it with 2,071 shares valued at $316,000.
• Institutional investors collectively own 69.55% of Johnson & Johnson's stock, with other large investors, including Precedent Wealth Partners LLC and Franklin Street Advisors Inc. NC, increasing their stakes in the company during the same period.
• Johnson & Johnson reported a quarterly earnings per share of $2.77, exceeding analysts' expectations, with revenue up 5.8% year-over-year, totaling $23.74 billion.

Fortis Capital Advisors LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 86.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,071 shares of the company's stock after selling 12,891 shares during the quarter. Fortis Capital Advisors LLC's holdings in Johnson & Johnson were worth $316,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Precedent Wealth Partners LLC raised its stake in Johnson & Johnson by 15.6% in the 2nd quarter. Precedent Wealth Partners LLC now owns 11,049 shares of the company's stock valued at $1,688,000 after purchasing an additional 1,489 shares during the last quarter. Franklin Street Advisors Inc. NC raised its position in shares of Johnson & Johnson by 5.1% in the second quarter. Franklin Street Advisors Inc. NC now owns 19,821 shares of the company's stock valued at $3,028,000 after buying an additional 968 shares during the last quarter. Barrett & Company Inc. lifted its stake in shares of Johnson & Johnson by 1.1% during the second quarter. Barrett & Company Inc. now owns 9,710 shares of the company's stock valued at $1,483,000 after buying an additional 105 shares during the period. HighMark Wealth Management LLC boosted its position in Johnson & Johnson by 21.9% during the second quarter. HighMark Wealth Management LLC now owns 1,167 shares of the company's stock worth $178,000 after acquiring an additional 210 shares during the last quarter. Finally, Abundance Wealth Counselors grew its stake in Johnson & Johnson by 12.7% in the 2nd quarter. Abundance Wealth Counselors now owns 20,903 shares of the company's stock worth $3,193,000 after acquiring an additional 2,363 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $188.51 on Monday. The firm's fifty day simple moving average is $176.18 and its 200 day simple moving average is $162.83. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $189.78. The firm has a market capitalization of $453.98 billion, a price-to-earnings ratio of 20.16, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the company posted $2.82 earnings per share. The firm's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the stock an "overweight" rating in a research note on Friday. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Johnson & Johnson in a research report on Saturday, September 27th. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Finally, Bank of America lifted their target price on Johnson & Johnson from $175.00 to $198.00 and gave the company a "neutral" rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $188.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.